Microbiology Testing Market Analysis

Microbiology Testing Market Analysis

To get key market trends

  Download Free Sample

Based on product, the microbiology testing market is segmented as instruments and reagents. Instruments dominated the microbiology testing market in 2022 accounting for more than 63% of the total business share. The instruments segment is poised to highlight substantial growth rate due to factors such as technological advancements, expanded testing volume, rapid and accurate result among others. Rising demand for instruments that offer automation and high-throughput capabilities to process a large number of samples in a shorter time frame, thereby improving efficiency and productivity in microbiology testing.

Moreover, rapid detection and analysis of pathogens, such as PCR machines, real-time PCR systems, next-generation sequencing platforms, and automated microbial identification systems, is expected to increase the product demand in several healthcare facilities.
 

Based on test type, the microbiology testing market is segmented as bacterial, viral, and fungal. The bacterial segment held a dominant market revenue of USD 2 billion in 2022. This high market share is owing to several clinical benefits offered by microbiology testing in the detection and diagnosis of bacterial disorders. E. coli bacteria is one of the common cause of Urinary tract infections. Therefore, clinical benefits offered by microbiology testing in diagnosis and treatment of bacterial infection is anticipated to fuel the market outlook.

Based on application, the microbiology testing market is segmented as respiratory diseases, bloodstream infection, gastrointestinal diseases, sexually transmitted diseases, urinary tract infections, periodontal diseases, and others. The respiratory diseases segment is forecasted to grow at 9% CAGR by 2032. The demand for microbiology testing in respiratory diseases has significantly increased, particularly due to the COVID-19 pandemic and the need to identify and manage other respiratory ailments.

Additionally, enhanced efficiency and accuracy in identification of other respiratory ailments such as pneumonia, tuberculosis, pertussis, influenza, respiratory syncytial virus (RSV), etc. have increased the product adoption in several healthcare facilities globally. Microbiology testing enables identification of drug-resistant strains, determine the efficacy of vaccines, control outbreaks and conduct research and public health monitoring.

Based on end-use, the microbiology testing market is segmented as hospitals, diagnostic centers, ambulatory surgical centers, and others. The hospital segment is projected to grow at 9.3% CAGR from 2023-2032. This high market share is owing to the availability of advanced microbiology testing instruments and kits for the diagnosis and treatment of varied chronic ailments. Enhanced operability and accessibility to comprehensive range of tests is expected to drive the market growth. Routine blood check-ups, sample tests, and other common diagnostic tests can be easily availed at such hospitals thus, proving beneficial for the industry progression.

Additionally, incorporation of advance microbiology instruments coupled with rising healthcare expenditure in several countries will increase the product adoption rate. Owing to these developments along with the rising number of diseases population, the demand for microbiology testing has significantly increased in hospitals. Thus, accessibility to better treatment & diagnosis coupled with the rising prevalence of chronic disorders will boost patient visits to hospitals.

The U.S. microbiology testing market is predicted to reach around USD 4.4 billion by 2032. This market share is attributable to numerous variables including the presence of key market players, an increase in the number of chronic diseases, and rising awareness regarding the benefits of microbiology testing for diagnosis and treatment of infectious diseases among others. For instance, according to the American Gastroenterological Association report, in 2021, around 60 million people in America were suffering from gastrointestinal (GI) diseases and is expected to increase in the near future.

Microbiology testing equipment help in identifying the epidemiology of these disorders and provide accurate result to healthcare professionals in designing and monitoring plan of action and course of treatment. The higher incidence of these diseases has resulted in the surged number of disease screening procedures that is anticipated to fuel the product adoption rate thereby, further accelerating the business trends.